Abstract
Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm(2) in the TELMI group (p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm(2), the change was not significant (p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan.
References
Mar 1, 2003·Diabetes Care·Earl S Ford, Wayne H Giles
Mar 26, 2003·Annual Review of Nutrition·Leslie Sue Lieberman
Nov 25, 2003·Diabetes & Metabolism·B BalkauUNKNOWN D.E.S.I.R. Study Group
Mar 10, 2004·Hypertension·Stephen C BensonTheodore W Kurtz
May 1, 2004·Circulation·Michael SchuppUlrich Kintscher
Dec 23, 2004·Journal of Hypertension·Theodore W Kurtz, Michal Pravenec
Sep 15, 2005·Circulation·Scott M GrundyUNKNOWN National Heart, Lung, and Blood Institute
Nov 25, 2005·Diabetes·Michael SchuppUlrich Kintscher
Mar 29, 2006·Hypertension·Ken SugimotoTheodore W Kurtz
May 24, 2006·Hypertension·Kana ArakiHironobu Yoshimatsu
Mar 14, 2007·Journal of Hypertension·Michio ShimabukuroTakeshi Shimabukuro
Mar 28, 2007·American Journal of Hypertension·Yutaka MoriNaoko Tajima
Mar 18, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Daisuke ChujoJunji Kobayashi
May 14, 2008·Journal of Hypertension·Ken SugimotoMichal Pravenec
Apr 24, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Hiroshi KudoToshiro Sugiyama
Oct 20, 2010·Cardiovascular Diabetology·Anna Foryst-LudwigUlrich Kintscher
Mar 24, 2011·Endocrinology·Shiho FujisakaKazuyuki Tobe
Oct 12, 2011·Journal of Hypertension·Takashi KajiyaTheodore W Kurtz
Nov 30, 2011·Korean Circulation Journal·Sung Yoon LimDong Joo Oh
Citations
Jan 25, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hisato TakagiUNKNOWN ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
May 30, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Michael A Ferguson, Joseph T Flynn
Aug 26, 2014·Journal of the American Society of Hypertension : JASH·Hisato TakagiUNKNOWN All-Literature Investigation of Cardiovascular Evidence Group
Nov 3, 2015·Magnetic Resonance Imaging·Simona KratochvílováTerezie Pelikánová
Mar 26, 2013·Journal of the American Society of Hypertension : JASH·Hisato TakagiUNKNOWN ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
Aug 16, 2015·Journal of Diabetes and Its Complications·Vasilios G Athyros, Dimitri P Mikhailidis
Mar 5, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Csaba András Dézsi
Mar 25, 2016·Current Medical Research and Opinion·Geun Joo ChoiJaetaek Kim
Dec 12, 2012·International Journal of Cardiology·Hisato TakagiUNKNOWN for ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
Jan 13, 2015·Biochemical Pharmacology·Yi LiJieshou Li
Sep 25, 2014·Annual Review of Pharmacology and Toxicology·R D FeldmanS W Tobe
Feb 22, 2017·Biological Reviews of the Cambridge Philosophical Society·Juan M ZolezziNibaldo C Inestrosa
Mar 21, 2018·American Journal of Therapeutics·Yan WangJing Yang